MedTrace Logo

Fish Gelatin Supplement and Omega-3 Supplement in Obese or Overweight Subjects With Insulin Resistance

NCT01215903 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2010-10-25

No results posted yet for this study

Summary

The present study was conducted to test whether a fish gelatin supplement combined with an omega-3 polyunsaturated fatty acid supplement can exert beneficial and sex-specific effects on insulin sensitivity, glucose tolerance, indicators of insulin secretion, blood pressure, lipid metabolism, inflammation and energy intake in obese or overweight insulin-resistant men and women. The investigators hypothesis is that fish gelatin improves insulin sensitivity, glucose tolerance, lipid profile and reduces inflammation in obese or overweight insulin-resistant men and women.

Conditions

Interventions

DIETARY_SUPPLEMENT

Fish gelatin and omega-3 polyunsaturated fatty acid

DIETARY_SUPPLEMENT

Omega-3 polyunsaturated fatty acid

Sponsors & Collaborators

  • Advance Foods and Materials Network

    collaborator OTHER

  • Institut des Nutraceutiques et Aliments fonctionnels, Quebec (Clinical nutrition facilities)

    collaborator UNKNOWN

  • University of Guelph

    collaborator OTHER

  • Ocean Nutrition Canada, Halifax (in-kind support: omega-3 supplements)

    collaborator UNKNOWN

  • Kenney & Ross

    collaborator OTHER

  • Laval University

    lead OTHER

Principal Investigators

  • Helene Jacques, PhD · Laval University

  • Andre Marette, PhD · Laval University

  • John S Weisnagel, MD/FRCPC · Laval University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01215903 on ClinicalTrials.gov